Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease

Sheykhhasan, Mohsen; Amini, Razieh; Asl, Sara Soleimani; Saidijam, Massoud; Hashemi, Seyed Mahmoud; Najafi, Rezvan

doi:10.1016/j.biopha.2022.113224

Cited by 35 publications

(17 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, recent studies give attention to MSC-derived exosomes as potential therapeutic agents due to their immunomodulatory [3 & ] and neuroprotective [70] effects. MSC-derived exosomes reduced disease pathology and improved cognitive dysfunction in AD, PD, and VaD [37][38][39]41,42,44,53,54,57,67]. To enhance therapeutic efficacy of MSC-derived exosomes, MSC preconditioning (or priming) strategies such as 3D culture, hypoxic culture, treatment of cytokines or chemicals, and gene modification are being tested [71,72].…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have shown therapeutic effects of active pharmaceutical ingredient (API)encapsulated exosomes in AD and PD [37,43,58,59]. As Sheykhhasan et al [37] shows, synergistic effects can be expected when loading API in MSC-derived exosomes. Because exosomes can penetrate the BBB, direct delivery of exosomes into the brain through intranasal route could be a potential treatment for dementia [55].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Exosomes for the diagnosis and treatment of dementia

Joo

Jeon

Hong³

et al. 2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

Purpose of reviewDementia is a syndrome with several possible pathologies. To date, definitive methods for diagnosis and treatment of sub-types of dementia have not been established. Emerging evidence suggests that exosomes can provide important information for the diagnosis and treatment of several subtypes of dementia. This article reviews recent studies on the application of exosomes in dementia.Recent findingsExosomes are involved in the pathogenesis of Alzheimer's disease (AD) and Parkinson's disease (PD) through transporting toxic proteins such as amyloid beta (Aβ), tau, and α-synuclein. Exosomal microRNAs (miR) and proteins reflect the disease state, and therefore, exosomes can be used as diagnostic markers for diseases such as AD, PD, Huntington's disease (HD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal dementia (FTD). Mesenchymal stem cell (MSC)-derived exosomes have been shown to ameliorate disease pathology, and improve cognitive function in AD, PD, and VAD.SummaryRecent studies have shown that exosomes could be novel diagnostic agents for dementia because they contain molecules that could be potential biomarker candidates indicative of the type and stage of dementia. Therapeutic application of exosomes in dementia has revealed that exosomes only, or exosomes loaded with an active pharmaceutical ingredient (API), ameliorate disease phenotype of dementia. Further work is needed to exploit this potential.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Exosomes for the diagnosis and treatment of dementia

Joo

Jeon

Hong³

et al. 2023

Current Opinion in Psychiatry

View full text Add to dashboard Cite

show abstract

“…The simplest way to load cargo into EXs is to incubate the desired cargo with EXs or EX-secreting cells to allow the cargo to diffuse into the EXs, following its concentration gradient. Several types of cargo, such as small molecule drugs, nucleic acids, proteins, and peptides have been loaded into EXs using this method [ 119 , 120 , 121 ]. Notably, BDNF has been loaded into macrophage-derived EXs and delivered into the brain [ 120 ] while the anti-inflammatory and anti-oxidative stress agent, co-enzyme Q10, has been loaded into EXs obtained from adipose-derived stem cells [ 121 ].…”

Section: Strategies To Load Exs With Therapeutic Cargomentioning

confidence: 99%

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease

Rademacher

2023

Biomedicines

View full text Add to dashboard Cite

Pathogenic forms of α-synuclein (α-syn) are transferred to and from neurons, astrocytes, and microglia, which spread α-syn pathology in the olfactory bulb and the gut and then throughout the Parkinson’s disease (PD) brain and exacerbate neurodegenerative processes. Here, we review attempts to minimize or ameliorate the pathogenic effects of α-syn or deliver therapeutic cargo into the brain. Exosomes (EXs) have several important advantages as carriers of therapeutic agents including an ability to readily cross the blood–brain barrier, the potential for targeted delivery of therapeutic agents, and immune resistance. Diverse cargo can be loaded via various methods, which are reviewed herein, into EXs and delivered into the brain. Genetic modification of EX-producing cells or EXs and chemical modification of EX have emerged as powerful approaches for the targeted delivery of therapeutic agents to treat PD. Thus, EXs hold great promise for the development of next-generation therapeutics for the treatment of PD.

show abstract

“…Better CoQ10 brain distribution and peak plasma concentration were achieved in rat models using a self-microemulsifying drug delivery system of CoQ10 compared to the coenzyme Q10 suspension [ 61 ]. Sheykhhasan et al reported a positive effect of CoQ10 drug delivery with the use of exosomes derived from adipose-derived stem cells (ADSCs-Exo) in a rat model of Alzheimer’s disease [ 62 ].…”

Section: Primary Coenzyme Q10 Deficiency-4mentioning

confidence: 99%

COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency

et al. 2022

View full text Add to dashboard Cite

COQ8A-ataxia is a mitochondrial disease in which a defect in coenzyme Q10 synthesis leads to dysfunction of the respiratory chain. The disease is usually present as childhood-onset progressive ataxia with developmental regression and cerebellar atrophy. However, due to variable phenotype, it may be hard to distinguish from other mitochondrial diseases and a wide spectrum of childhood-onset cerebellar ataxia. COQ8A-ataxia is a potentially treatable condition with the supplementation of coenzyme Q10 as a main therapy; however, even 50% may not respond to the treatment. In this study we review the clinical manifestation and management of COQ8A-ataxia, focusing on current knowledge of coenzyme Q10 supplementation and approach to further therapies. Moreover, the case of a 22-month-old girl with cerebellar ataxia and developmental regression will be presented.

show abstract

Neuroprotective effects of coenzyme Q10-loaded exosomes obtained from adipose-derived stem cells in a rat model of Alzheimer's disease

Cited by 35 publications

References 39 publications

Exosomes for the diagnosis and treatment of dementia

Exosomes for the diagnosis and treatment of dementia

Potential for Therapeutic-Loaded Exosomes to Ameliorate the Pathogenic Effects of α-Synuclein in Parkinson’s Disease

COQ8A-Ataxia as a Manifestation of Primary Coenzyme Q Deficiency

Contact Info

Product

Resources

About